Fibroblast Activation Protein Inhibitor Theranostics
Authors:
- 6 April 2023
- journal article
- research article
- Published by Elsevier in PET Clinics
- Vol. 18 (3) , 419-428
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re TherapyJournal of Nuclear Medicine, 2020
- Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor RetentionJournal of Nuclear Medicine, 2019
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation ProteinJournal of Nuclear Medicine, 2018
- A Tumor-Imaging Method Targeting Cancer-Associated FibroblastsJournal of Nuclear Medicine, 2018
- Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffoldMedChemComm, 2014
- Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)Journal of Medicinal Chemistry, 2014
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancerProceedings of the National Academy of Sciences, 2013
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Inflammatory Response in Cervicallntraepithelial Neoplasia and Squamous Cell Carcinoma of the Uterine CervixPathology - Research and Practice, 1997